Alkeus Pharmaceuticals
Clinical-stage biotechnology company developing gildeuretinol (ALK-001) for the treatment of Stargardt disease and other inherited retinal degenerations.
Website
https://www.alkeuspharma.comLocation
Boston, Massachusetts, USA
Founded
2010
Categories
biotech, rare-disease, ophthalmology, therapeutics
Notes
Alkeus Pharmaceuticals is a clinical-stage biotechnology company focused on developing treatments for Stargardt disease and other forms of inherited retinal degenerations. The company's lead candidate, gildeuretinol (ALK-001), is a modified vitamin A designed to slow the accumulation of toxic vitamin A dimers (A2E) in the retinal pigment epithelium.
Stargardt disease is the most common form of inherited juvenile macular degeneration, affecting approximately 1 in 10,000 people worldwide. ALK-001 has received FDA Orphan Drug and Fast Track designations.
Team
- Leonide Saad, Ph.D. - Founder & Chief Executive Officer
- LinkedIn: linkedin.com/in/leonidesaad
- Konstantin Bhbat, Ph.D. - Co-founder
Additional Research Findings
- In Bain Capital Life Sciences portfolio
- Lead candidate gildeuretinol (ALK-001) in Phase 3 for Stargardt disease
- FDA Orphan Drug Designation for ALK-001
- FDA Fast Track Designation for Stargardt disease
- Technology based on research from Columbia University
- Targeting the vitamin A cycle to prevent retinal degeneration
- Also exploring ALK-001 for dry age-related macular degeneration (AMD)